td-8954

Small moleculeexperimental

Clinical trial activity

2 trials · 1 clinical orgs · 0 marketing orgs

Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0

Earliest trial started Sep 1, 2012 (NCT01644240)

Timeline

2010s

  1. Jan 1, 2012

    Earliest Phase 1 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Also known as

  • 4-((4-((2-isopropyl-1h-benzoimidazole-4-carbonyl)amino)methyl)piperidin-1-ylmethyl)piperidine-1-carboxylic acid methyl ester
  • td-8954
  • td-8954
  • td-8954
  • td-8954

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT01953081Phase 1/Phase 2 (Phase 2)Jan 1, 2014Theravance
NCT01644240Phase 1Sep 1, 2012Theravance
Showing 2 of 2 trials
Page 1 / 1

Organizations

Research & Development (1)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
TheravanceFor profit2222012
1 organizations
Page 1 / 1